In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
Multiple myeloma is still an incurable hematological malignancy of monoclonal B-lymphocytes. While standard chemotherapy regimens have been used for years, novel agents like lenalidomide and bortezomib have become an essential part of today's therapies and significantly improve therapeutic efficacy. Nevertheless, new therapeutic strategies are still indispensable. Aberrant activation of Wnt/β-catenin signaling promotes development of several cancers. Recently, it has been demonstrated that the Wnt pathway is activated in both lymphoma and myeloma. Thus, Wnt signaling molecules are attractive candidates for the development of new targeted-therapies. Naftifine was used in the present study since it has chemical features similar to those of other known WNT inhibitors. The anti-tumor apoptotic effect of naftifine at doses ranging from 0.1-200 μM was investigated on two human and one murine lymphoma, as well as in one murine and three human myeloma cell lines, and determinded by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) assay. Naftifine significantly reduced cell viability in all tested myeloma and lymphoma cell lines in a dose-dependent manner, while healthy cells were only slightly affected. Naftifine exhibits toxicity to hematological neoplasms in vitro.